GlaxoSmithKline plc Given Consensus Recommendation of “Hold” by Analysts (LON:GSK)
Shares of GlaxoSmithKline plc (LON:GSK) have earned an average recommendation of “Hold” from the twenty-three analysts that are covering the company, American Banking News reports. Four investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 1,726.48 ($29.41).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1575.50 on Tuesday. GlaxoSmithKline plc has a 52 week low of GBX 1200.668 and a 52 week high of GBX 1762.0001. The stock has a 50-day moving average of GBX 1602. and a 200-day moving average of GBX 1614.. The company’s market cap is £75.845 billion.
A number of analysts have recently weighed in on GSK shares. Analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. They now have a GBX 2,100 ($35.77) price target on the stock. Separately, analysts at Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, June 20th. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Thursday, June 19th. They now have a GBX 1,610 ($27.42) price target on the stock.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.